-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Financial App News, Weilizhibo-B (09887.HK) announced that the China National Drug Administration (NDRA) Drug Evaluation Center (CDE) has approved its self-developed drug candidate Vilisin™ (PD-L1/4-1BB bispecific antibody opatisumimab, LBL-024) for the treatment of metastatic colorectal cancer (mCRC). The approved clinical trial is an open-label, multicenter phase IB/II study to evaluate the safety and efficacy of Virixine™ in combination therapy for mCRC. This milestone marks an important step in expanding the indications of Villisin™ in gastrointestinal tumors. The company's immunotherapy landscape further extends from biliary tract cancer (BTC), gastric cancer (GC), and esophageal squamous cell carcinoma (ESCC) to colorectal cancer (CRC), a type of cancer with highly unmet clinical needs.

Zhitongcaijing·08/02/2026 22:17:01
Listen to the news
Zhitong Financial App News, Weilizhibo-B (09887.HK) announced that the China National Drug Administration (NDRA) Drug Evaluation Center (CDE) has approved its self-developed drug candidate Vilisin™ (PD-L1/4-1BB bispecific antibody opatisumimab, LBL-024) for the treatment of metastatic colorectal cancer (mCRC). The approved clinical trial is an open-label, multicenter phase IB/II study to evaluate the safety and efficacy of Virixine™ in combination therapy for mCRC. This milestone marks an important step in expanding the indications of Villisin™ in gastrointestinal tumors. The company's immunotherapy landscape further extends from biliary tract cancer (BTC), gastric cancer (GC), and esophageal squamous cell carcinoma (ESCC) to colorectal cancer (CRC), a type of cancer with highly unmet clinical needs.